In this context, Cuadros et al. showed a potential benefit of anti-CD137 and anti-OX40 antibodies in enhancing the immune responses in combination with dendritic cell-based vaccines in a Her-2/neu tumor model. This evidence concerns the gene TNFRSF4 and neoplasm.